公开(公告)号：US12090253B2

公开(公告)日：2024-09-17

申请号：US16728138

申请日：2019-12-27

申请人： VeriGraft AB

发明人： Suchitra Sumitran-Holgersson ,  Michael Olausson

IPC分类号： A61L27/50 ,  A61F2/06 ,  A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K35/34 ,  A61K35/44 ,  A61K35/545 ,  A61L27/24 ,  A61L27/36 ,  A61L27/38 ,  A61L27/54 ,  C12N5/071 ,  C12N5/078

CPC分类号： A61L27/507 ,  A61K35/14 ,  A61K35/28 ,  A61K35/34 ,  A61K35/44 ,  A61K35/545 ,  A61L27/24 ,  A61L27/3616 ,  A61L27/3625 ,  A61L27/3808 ,  A61L27/3826 ,  A61L27/3834 ,  A61L27/3886 ,  A61L27/54 ,  C12N5/0641 ,  C12N5/0691 ,  C12N5/0692 ,  A61F2/06 ,  A61F2/062 ,  A61F2240/001 ,  A61K2035/124 ,  A61L2300/252 ,  A61L2300/64 ,  A61L2430/34 ,  C12N2533/54 ,  C12N2533/90

摘要： The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases.

公开(公告)号：US12090173B2

公开(公告)日：2024-09-17

申请号：US18054364

申请日：2022-11-10

申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

发明人： Robert Sackstein

IPC分类号： A61K35/30 ,  A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K35/32 ,  A61K35/33 ,  A61K35/34 ,  A61K35/35 ,  A61K35/37 ,  A61K35/407 ,  A61K35/42 ,  C12N5/00

CPC分类号： A61K35/30 ,  A61K35/14 ,  A61K35/28 ,  A61K35/32 ,  A61K35/33 ,  A61K35/34 ,  A61K35/35 ,  A61K35/37 ,  A61K35/407 ,  A61K35/42 ,  C12N5/0006 ,  A61K2035/124 ,  C12N2501/724

摘要： Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression.

公开(公告)号：US20240238406A1

公开(公告)日：2024-07-18

申请号：US18540621

申请日：2023-12-14

申请人： American Gene Technologies International Inc.

发明人： Charles David Pauza ,  Haishan Li ,  Tyler Lahusen ,  Gary Mansfield

IPC分类号： A61K39/21 ,  A61K31/7105 ,  A61K35/12 ,  A61K35/14 ,  A61K35/15 ,  A61K35/17 ,  A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61P31/18 ,  C07K14/715 ,  C12N5/078 ,  C12N5/0783 ,  C12N7/00 ,  C12N15/11 ,  C12N15/113 ,  C12N15/86

CPC分类号： A61K39/21 ,  A61K31/7105 ,  A61K35/14 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61P31/18 ,  C07K14/7158 ,  C12N5/0634 ,  C12N5/0636 ,  C12N7/00 ,  C12N15/111 ,  C12N15/1132 ,  C12N15/1138 ,  C12N15/86 ,  A61K2035/124 ,  A61K35/15 ,  A61K35/17 ,  A61K2039/5156 ,  A61K2039/545 ,  A61K2039/55561 ,  C12N2310/122 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/32 ,  C12N2330/51 ,  C12N2510/00 ,  C12N2710/24143 ,  C12N2740/15021 ,  C12N2740/15034 ,  C12N2740/15043 ,  C12N2740/15052 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16043

摘要： The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

公开(公告)号：US20240226403A1

公开(公告)日：2024-07-11

申请号：US18561569

申请日：2022-04-12

申请人： KANEKA CORPORATION ,  Broad Bean Science Co., LTD.

发明人： Yuta FUJITA ,  Makoto KUROO

IPC分类号： A61M1/36 ,  A61K35/14 ,  A61P7/08

CPC分类号： A61M1/3633 ,  A61K35/14 ,  A61P7/08 ,  A61M2202/0413

摘要： The objective of the present invention is to provide a treatment material for the treatment of a disease of which symptom is alleviated or treated by reducing a blood phosphorus concentration. The treatment material according to the present invention is characterized in comprising a water-insoluble carrier and 1 or more adsorbing groups selected from the group consisting of a phosphate group, a phosphonate group, a phosphinate group, an amino group, a carboxy group and a thiol group, wherein the adsorbing group binds to the water-insoluble carrier through a linker group, the treatment material is used for treating a disease, wherein a symptom of the disease is alleviated or treated by reducing a blood phosphorus concentration, and dialyzed blood is passed through the treatment material to adsorb a calciprotein particle in the dialyzed blood on the adsorbing group, or blood is passed through the treatment material and then dialyzed.

公开(公告)号：US20240123027A1

公开(公告)日：2024-04-18

申请号：US18360975

申请日：2023-07-28

申请人： ABIONYX PHARMA SA

发明人： Jean-Louis DASSEUX

IPC分类号： A61K38/17 ,  A61K35/14 ,  A61K45/06 ,  A61K47/24 ,  A61P1/16 ,  A61P3/06 ,  A61P9/10 ,  A61P43/00 ,  C07K14/775 ,  C07K19/00

CPC分类号： A61K38/1709 ,  A61K35/14 ,  A61K45/06 ,  A61K47/24 ,  A61P1/16 ,  A61P3/06 ,  A61P9/10 ,  A61P43/00 ,  C07K14/775 ,  C07K19/00

摘要： Apomers comprising apolipoprotein molecules complexed with amphipathic molecules and uses thereof for treating dyslipidemic and liver disorders.

公开(公告)号：US20240122987A1

公开(公告)日：2024-04-18

申请号：US18379740

申请日：2023-10-13

申请人： THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY

发明人： Andrew P. CAP ,  James A. BYNUM ,  Xiaowu WU

IPC分类号： A61K35/19 ,  A61K9/00 ,  A61K31/137 ,  A61K31/437 ,  A61K31/4418 ,  A61K31/472 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K38/04 ,  A61K38/095 ,  A61K38/36 ,  A61K38/38 ,  A61K47/26 ,  A61P7/04

CPC分类号： A61K35/19 ,  A61K9/0019 ,  A61K31/137 ,  A61K31/437 ,  A61K31/4418 ,  A61K31/472 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K35/14 ,  A61K35/16 ,  A61K35/18 ,  A61K38/043 ,  A61K38/095 ,  A61K38/363 ,  A61K38/38 ,  A61K47/26 ,  A61P7/04

摘要： A majority of military casualties occur during the pre-hospital period. The cause of death is largely associated with massive traumatic bleeding that leads to organ damage due to sustained hypoxia. Currently, therapeutics are lacking at the point of injury to mitigate hypoxic damage and maintain the survivability of severe hemorrhage prior to reaching medical facilities. This invention addresses that by introducing a method of co-administering prolyl hydroxylase domain inhibitor (PHDi, MK-8617), anti-fibrinolytic agent (tranexamic acid), and bradykinin receptor antagonist (icatibant) as anti-hemorrhage agents in combination with resuscitation fluid treatment with colloid solution of 25% human albumin that has an advantage of relatively small volume requirement to maintain blood volume. In addition, a kit comprising anti-hemorrhage agents that can be easily carried to the battlefield is also provided here. The therapeutic application of those agents on or near the point of injury can stabilize hypoxia inducible factor-1 alpha and enhance blood clot formation, which improves the patient's cellular adaptation to hypoxia and reduce hemorrhage, and thus can decrease organ failure and increase the patient's survivability.

公开(公告)号：US11957384B2

公开(公告)日：2024-04-16

申请号：US17510653

申请日：2021-10-26

申请人： PROGENA INC.

发明人： Alexander Feskov ,  Irina Feskova ,  Ievgeniia Zhylkova ,  Stanislav Zhilkov

IPC分类号： A61B17/435 ,  A61D19/00 ,  A61D19/04 ,  A61K35/14 ,  C12N5/078 ,  A61K35/12

CPC分类号： A61B17/435 ,  A61D19/00 ,  A61D19/04 ,  A61K35/14 ,  C12N5/0634 ,  A61K2035/124 ,  C12N2501/31

摘要： A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.

公开(公告)号：US11872195B2

公开(公告)日：2024-01-16

申请号：US16222942

申请日：2018-12-17

申请人： FRED HUTCHINSON CANCER CENTER

发明人： Matthias Stephan ,  Howell F. Moffett

IPC分类号： A61K48/00 ,  C12N9/22 ,  C07K14/705 ,  C12N15/88 ,  A61K35/14

CPC分类号： A61K48/005 ,  C07K14/705 ,  C12N9/22 ,  C12N15/88 ,  A61K35/14

摘要： Compositions and methods that rapidly and selectively modify hematopoietic stem cells (or cells derived therefrom) to achieve therapeutic objectives by providing for transient expression of nucleic acids are described. The transient expression leads to permanent therapeutic changes in the modified cells, referred to herein as “hit and run” effects.

公开(公告)号：US11850313B2

公开(公告)日：2023-12-26

申请号：US17127965

申请日：2020-12-18

申请人： The London Health Sciences Centre Research Inc.

发明人： Alp Sener ,  Smriti Juriasingani

IPC分类号： A01N1/02 ,  A61K31/67 ,  A61K33/04 ,  A61K35/14 ,  A61K38/42 ,  A61L2/00

CPC分类号： A61L2/0088 ,  A01N1/0226 ,  A61K31/67 ,  A61K33/04 ,  A61K35/14 ,  A61K38/42

摘要： A tissue oxygenation composition comprising (a) an oxygenated solution or a solution containing an oxygen carrier and (b) hydrogen sulfide (H2S). The disclosure also relates to methods of preserving, reperfusing and/or transfusing tissue with a tissue oxygenation composition according to the present disclosure.

公开(公告)号：US20230355180A1

公开(公告)日：2023-11-09

申请号：US17805839

申请日：2022-06-07

申请人： HDL Therapeutics, Inc.

发明人： Hollis Bryan Brewer, JR. ,  Michael M. Matin

IPC分类号： A61B5/00 ,  A61M1/00 ,  A61K35/14 ,  A61M1/02 ,  A61M1/36 ,  A61B5/02 ,  A61F2/82 ,  A61L31/16

CPC分类号： A61B5/6866 ,  A61M1/00 ,  A61K35/14 ,  A61M1/0281 ,  A61M1/3687 ,  A61M1/3607 ,  A61B5/02007 ,  A61F2/82 ,  A61L31/16 ,  A61M2202/0458 ,  A61M2202/0456 ,  A61L31/10

摘要： The present specification is directed to systems, apparatus and methods for treating lipid-related diseases including homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, ischemic stroke, coronary artery disease, acute coronary syndrome, peripheral arterial disease, or renal arterial disease and its complications, and for treating the progression of Alzheimer's disease using imaging techniques to assess changes in one or more lipid-containing atheroma areas and volumes after serial infusions of delipidated plasma as compared to a baseline